Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of circRBM39 as a tumor suppressor in breast cancer

ABSTRACT: Identification of circRBM39 as a tumor suppressor in breast cancer

PROVIDER: PRJNA1224764 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32369873_1.fastq.gz	Fastqsanger.gz
	SRR32369873_2.fastq.gz	Fastqsanger.gz
	SRR32369874_1.fastq.gz	Fastqsanger.gz
	SRR32369874_2.fastq.gz	Fastqsanger.gz
	SRR32369875_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Genome stability disrupted by the circRBM39-RPA2 axis represses breast tumorigenesis

Project description:Genome instability (GI) is a hallmark of cancer. GI is associated with accumulative DNA damage and tumor-specific defects in DNA repair. Multiple anti-tumor drugs have been developed to promote persistent GI and to drive DNA damage beyond a threshold that tumor cells can survive. However, regulatory roles of circRNAs in GI and DNA damage remain elusive. Through circRNA profiling and an siRNA-mediated screen, we have identified a circRNA termed circRBM39, which is significantly decreased in breast cancer (BC) and disrupts DNA damage response. CircRBM39 inhibits breast tumorigenesis through increasing DNA damage and promoting sensitivity to the anti-tumor drug PARP inhibitor (PARPi). Mechanistically, cytoplasmic circRBM39 interacts with replication protein A2 (RPA2), an essential DNA repair factor, through a 7-nt AG-rich motif and destabilizes RPA2 protein by facilitating HERC2-mediated ubiquitination, thus repressing homologous recombination repair. Importantly, administration of in vitro synthesized circRBM39 substantially inhibits breast tumorigenesis, sensitizes BC cells to PARPi, and renders them susceptible to synthetic lethality (SL) in distinct breast tumorigenesis mouse models. Our findings highlight the interplay between circRNA and GI in cancers, and the SL of circRBM39 to PARPi provides new strategies for RNA-based BC therapeutics.

2025-02-22 | GSE289776 | GEO

SIRT7 safeguards genome stability and suppresses colorectal tumorigenesis

Project description:SIRT7 safeguards genome stability and suppresses colorectal tumorigenesis

| PRJNA575347 | ENA

A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis

Project description:A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis

| PRJNA1161652 | ENA

Aging represses oncogenic KRAS-driven lung tumorigenesis and alters tumor suppression

Project description:Aging represses oncogenic KRAS-driven lung tumorigenesis and alters tumor suppression

| PRJNA1262399 | ENA

JAB1/CRL4B Complex Represses PPARG/ACSL5 Expression to Promote Breast Tumorigenesis

Project description:JAB1/CRL4B Complex Represses PPARG/ACSL5 Expression to Promote Breast Tumorigenesis

| PRJNA1216176 | ENA

Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis.

Project description:Prep1 is a tumor-suppressor, whereas Meis1 is an oncogene. We show that to perform these activities in MEFs both proteins competitively hetero-dimerize with Pbx1. Meis1 alone transforms Prep1-deficient fibroblasts while Prep1 overexpression inhibits Meis1 tumorigenicity. Pbx1 can therefore alternatively act as oncogene or tumor-suppressor. Prep1 post-translationally controls the level of Meis1 decreasing its stability by sequestering Pbx1. The different levels of Meis1 and the presence of Prep1 are followed at the transcriptional level by the induction of specific transcriptional signatures. The decrease of Meis1 prevents Meis1 interaction with Ddx3x and Ddx5, which are essential for Meis1 tumorigenesis, and modifies the growth promoting DNA binding landscape of Meis1 to the growth controlling landscape of Prep1. Hence the key feature of Prep1 tumor inhibiting activity is the control of Meis1 stability. Examination of Prep1 and Meis1 in three cell type

2014-03-05 | E-GEOD-54221 | biostudies-arrayexpress

Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis [hP]

2016-06-01 | E-GEOD-58802 | biostudies-arrayexpress

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs

Project description:An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs

| PRJNA1466570 | ENA

Project description:Genomic instability is a prominent driver of tumorigenesis. However, a significant fraction of human cancers display few genomic aberrations, suggesting alternative roads towards malignancy. Here, we show that the differentiation status of normal human mammary epithelial cells influences the early response to an oncogenic activation and determines the genetic routes towards tumorigenesis. Following an oncogenic insult, luminal progenitors and differentiated luminal cells undergo oxidative and DNA replication stress, initiating genomic instability. In contrast, mammary stem cells exhibit the innate capacity to withstand aberrant mitogenic activation, fostering malignant transformation. This property relies upon a pre-emptive program driven by the ZEB1 transcription factor and the methionine sulfoxide reductase MSRB3. The ZEB1-MSRB3 axis governs cellular pliancy and prevents the continuous formation of oncogene-induced DNA damage, leading to neoplasms with unique pathological features. These gene expression data correspond to the different subpopulations that compose the hierarchy of normal human mammary epithelial cells. These subpopulations were freshly isolated from mammary tissue, originating from reduction mammoplasties and flow sorted using four markers (EpCAM, CD10, CD49f, ALDH). Three subpopulations enriched in mammary stem cells (MaSCs) are designed as MaSC1, 2, 3; the luminal progenitor are designed as LP, and the mature luminal cells as mL1 and mL2.

2017-03-23 | E-MTAB-4145 | biostudies-arrayexpress

YTHDF1-N6-methyladenosine-ARHGEF2 axis promoted colorectal tumorigenesis and metastasis

Project description:YTHDF1-N6-methyladenosine-ARHGEF2 axis promoted colorectal tumorigenesis and metastasis

| PRJNA668907 | ENA